Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more
Texas Retina Honors Founder Dr. Vaiser with Donation to Retina Foundation
On behalf of the entire Texas Retina team, Gary Edd Fish, MD, recently presented a $2,000 donation to the Retina Foundation to honor the 90th birthday of one of Texas Retina’s founders,
read more
Dr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for
read more Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial
On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific
read more
Dr. Wang Presented Initial Study Results of New Non-infectious Uveitis Treatment at ASRS 2024 Annual Meeting
Texas Retina’s Robert C. Wang, MD, presented “Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase II Study (NEPTUNE)” at the 2024 Annual
read more
Dr. Abbey Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read more Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology
At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand
read more
Texas Retina Recognizes Laurie Griffis for 35 Years of Service
Since Texas Retina was founded more than 50 years ago, our physicians and leadership have fostered a family environment. As a result, we are fortunate to have numerous team members who have
read more
New Clinical Trials Available at Texas Retina
At Texas Retina Associates, we remain committed to conducting ongoing research that will improve care for our patients, and over the past 20 years, our research program has grown to become one
read more
Celebrating Our Visionary Founders
Many of our “founding physicians” met for dinner this past weekend, including Albert Vaiser, MD, and William Hutton, MD, who along with William Snyder, MD, established Texas Retina Associates more than 50 years
read more